Feature|Articles|March 31, 2026

Regulatory recap: FDA approvals in urology from Q1 of 2026

Fact checked by: Benjamin P. Saylor, Strategic Content Lead

A recap of the FDA approvals and clearances across urology from January through March.

The first quarter of 2026 brought a wave of regulatory activity across the urology landscape, with 8 distinct FDA actions recorded between January and March. These regulatory approvals and clearances spanned both benign and oncologic indications, reflecting continued momentum in both device innovation and pharmacologic development across the field.